DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The FDA announced that it has approved patisiran infusion for the treatment of patients with peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis.
The treatment (Onpattro, Alnylam Pharmaceuticals) is the first of its kind to be approved by the FDA for patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, and the first FDA approval for small interfering ribonucleic acid treatment, according to a press release from the agency.
Hereditary transthyretin-mediated amyloidosis is a genetic disease that produces buildup of abnormal amyloid protein in peripheral nerves, the heart and elsewhere in the body, the FDA stated in the release.
“There has been a long-standing need for a treatment for hereditary transthyretin-mediated amyloidosis,” Billy Dunn, MD, director of the division of neurology products for the FDA’s Center for Drug Evaluation and Research, said in the press release. “This unique targeted therapy offers these patients an innovative treatment for their symptoms that directly affects the underlying basis of this disease.”
educationTips for Managing Your Professional Life With hATTR AmyloidosisTelling your employer about your hATTR a...
educationStress Management Following hATTR Amyloidosis DiagnosisLiving with hATTR amyloidosis can cause ...
educationInotersen Treatment for Patients With Hereditary Transthyretin AmyloidosisBackground: Hereditary transthyretin am...
videos & visualsAlnylam Clinical Trial Update – ASG Webinar 4/11https://www.youtube.com/watch?v=K2TmwAfu...
news & meetingsTwenty-Seven Family Members Tested in One Day Thanks to Young Caregiver Inspired by New TreatmentAngel loved growing up in a big, close-k...
educationTips for Living Your Best Life With hATTR AmyloidosisAfter being diagnosed with hATTR amyloid...
educationDiagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisTransthyretin amyloidosis is a fatal dis...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.